Cerdelga Approval History
Cerdelga (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long- term treatment of adult patients with Gaucher disease type 1.
Development History and FDA Approval Process for Cerdelga
|Aug 19, 2014||FDA Approves Cerdelga (eliglustat) for Type 1 Gaucher Disease|
|Dec 11, 2013||FDA Grants Priority Review for Genzyme’s Cerdelga (eliglustat), an Investigational Oral Therapy for Gaucher Disease|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.